Figure 4
From: Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis
GSK2830371 enhances Dox- and VP-16-induced cytotoxicity in p53 wild-type NB cell lines.
(a and c) IMR-32 and SH-SY5Y cells were seeded in 96-well plates and were incubated with the indicated concentrations of Dox plus DMSO or 20 μM of GSK2830371 for 48 hrs. Cell viability was then measured by the CCK-8 assay as described in Methods. (b and d) IMR-32 and SH-SY5Y cells were seeded in 96-well plates and were incubated with the indicated concentrations of VP-16 plus DMSO or 20 μM of GSK2830371 for 48 hrs. The cell viability was then measured by the CCK-8 assay. The results were represented as % vehicle ± S.D. P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***) (Student’s t-test, two-tailed) were indicated. (e) IMR-32 cells were treated with Dox (0.5 μM), or VP-16 (5 μM), or GSK2830371 (20 μM) alone, or their combinations for 8 hrs. (f) SH-SY5Y cells were treated with Dox (1 μM) alone, or VP-16 (5 μM), or GSK2830371 (20 μM) alone, or their combinations for 8 hrs. At the end of the treatment, cells were collected and then the lysates were subjected to SDS-PAGE, and immunoblotted with the indicated antibodies. β-Actin was used as a loading control for whole cell extracts in all samples. Each experiment was repeated for at least three times.
